Both stocks have huge opportunities still in front of them. When it comes to investing, sometimes you want to take a big swing. After all, it's not always the number of winners in your portfolio that ...

What Happened? A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1 ...

Hims and Hers stock rally looms with bullish EMAs, Novo Nordisk partnership, ZAVA acquisition, and new product launches ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

As more CFOs step into the public spotlight by participating in events and conferences, the cost of misspeaking and the importance of leadership alignment on policy are increasing.

Discover why Hims & Hers is leading the telehealth market with strong growth, a loyal user base, and expansion into new ...

Salem Investment Counselors Inc. bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities ...

Eli Lilly found itself in a pharmaceutical pickle after its CFO claimed telehealth partners don’t compound key weight-loss ...

The past six months have been a windfall for Hims & Hers Health’s shareholders. The company’s stock price has jumped 90%, ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Whether you want a medicated solution or an all-natural fix, these pro-backed recommendations can start helping in as little ...